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Abstract 
While some tumor cells are sensitive to the antiproliferative ffects of tumor necrosis factor (TNF), others are resistant. The molecular basis for 
cellular resistance to TNF is not completely understood. Previously we have shown that transfection of cells with an oncogene HER2haeulerb 82, 
a receptor tyrosine kinase, leads to resistance to the anticellular effects of TNF [(1988) Proc. Natl. Acad. Sci. USA 85, 5102-51061. In the present 
study, we demonstrate that the overexpression of another oncogenic tyrosine kinase, pp60” also induces resistance to TNF. In contrast to HER2, 
however, pp60” transfection of cells did not lead to down-modulation of TNF receptors but rather to decreased intracellular glutathione levels. 
The pp60”- induced cellular resistance to TNF could be abrogated by interferon-y. Thus, these results indicate that the resistance of certain tumors 
to TNF may also be due in part to the overexpression of pp60”“’ oncogene. 
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1. Introduction 
Tumor necrosis factor (TNF) a 17-kDa polypeptide 
produced by activated macrophages, is highly plei- 
otropic [l-3]. It inhibits the growth of different tumor 
cell types and stimulates the growth of certain normal 
cells in culture [3,4]. While several cell lines are highly 
sensitive to the antiproliferative effects of TNF, others 
are quite resistant. The molecular basis for this resistance 
is not understood but roles for manganese superoxide 
dismutase [5], growth factors [6], and glutathione [7] have 
been demonstrated. Interestingly, the expression of TNF 
itself by certain tumor cells has been shown to cause 
resistance to TNF [8]. 
The transforming gene of Rous sarcoma virus (RSV), 
v-src, encodes a 60-kDa phosphoprotein, pp60”‘, which 
is a tyrosine-specific protein kinase [9]. Its cellular ho- 
molog pp60” is localized on the inner surface of the 
plasma membrane, as well as, other intracellular mem- 
branes and represents the prototype of nonreceptor tyro- 
sine kinases. Several intracellular protein tyrosine ki- 
nases have been identified, that show a high degree of 
homology with the product of the protooncogene c-src. 
The receptors for several growth factors including epi- 
dermal growth factor, fibroblast growth factor, insulin- 
like growth factor and platelet-derived growth factor are 
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also tyrosine kinase. These kinases are overexpressed in 
various tissues, including hematopoietic ells [9]. 
Previously, we have shown that tumor cell lines that 
overexpress human epidermal growth factor receptor-2 
(HER-2lerb Blneu), a protein tyrosine kinase, are resis- 
tant to TNF and that transfection of cells with this onco- 
gene also induces resistance to this cytokine [lo]. In the 
present study, we investigated the effects of another tyro- 
sine kinase, pp60”, on the anticellular activity of TNF. 
We found that it also induced resistance to TNF. In 
constrast to HER2 kinase, however, resistance induced 
by v-src kinase was not due to modulation of TNF- 
receptors. Rather, cellular resistance to TNF correlated 
with the downmodulation of intracellular glutathione 
levels. 
2. Materials aud methods 
2.1. Materials 
Gentamicin and fetal calf serum (FCS) were obtained from Gibco, 
Grand Island, NY. DMEM was obtained from Whittaker MA Bio- 
products, Walkersville, MD. Bacteria-derived recombinant human 
TNF and murine interferon-y (IFN-7~) purified to homogeneity were 
kindly provided by Genentech Inc., South San Francisco, CA. Other 
chemical agents were purchased from Sigma Chemical Company (St. 
Louis, MO). 
2.2. Cells 
pp6tY*c- transfected NIH3T3 cells and the neomycin-transfected con- 
trol lines were the gift from Dr. Mark Smith from National Cancer 
Institute, Frederick Cancer Research Facility, Frederick, MD. Cells 
were routinely grown in DMEM supplemented with glutamine (2 mM), 
gentamicin (5O&nl), and FBS (10%) in a humidified incubator in 5% 
COa in air. Occasionally, the transfected cells were checked for neomy- 
cin resistance by including G418 (500 &ml) in the medium. 
2.3. Antiproliferation assays 
For growth inhibition assays, cells (5 x 103/well) were plated over- 
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night in 0.1 ml of DMEM with 10% FBS in 96-well Falcon plates. 
Thereafter, the medium was removed and a serial dilution of human 
TNF was layered in 0.1 ml of the medium. After 72 h incubation at 
37”C, the viable cells were monitored by Crystal violet staining accord- 
ing to the procedure as described [q. The relative cell viability was 
calculated as optical density in the presence of the test sample divided 
by optical density in the absence of the test sample (medium) and 
expressed as a percentage. 
2.4. Receptor-binding assay 
Binding assays were performed in 96well microplates (Falcon 3911, 
Becton Dickinson Labware, Oxnard, CA) as described [11,12]. 
2.5. Determination of intracellular glutathione levels 
The intracellular glutathione levels were determined by an ionex- 
change high-performance liquid chromatography method as described 
previously [131. Briefly, 3 x lo6 cells cultured were homogenized in 10% 
HClO, and centrifuged. The pellet was analyzed for protein by the 
method of Lowry and the supernatant was analyzed for glutathione 
content. All determinations were made in triplicate and the results were 
expressed as nanomoles of glutathione per mg of protein. 
2.6. Determination of ppbo’“” tyrosine kinase activity 
The activity of pp60” was assayed as described previously with 
minor modifications [14]. Briefly, enzyme was extracted from a pellet 
of 5 x lo6 cells in a detergent medium. pp60”’ was immunoprecipitated 
with monoclonal antibody clone 327 and the kinase activity of the 
immtmocomplex was determined in the absence (background control) 
and presence of 2 mg/ml poly E,Y as the substrate. The phosphate 
incorporation into the substrate was determined by acid precipitation 
of the “P-labeled product onto 3MM filter paper. A unit of kinase 
activity was defined as pmol of phosphate incorporated into poly E,,Y 
per minute. 
3. Results 
3.1. NIH-3T3 cells transfected with pp60vVs” overexpress 
tyrosine kinase activity and differ in morphology 
As shown in Fig. 1, cells transfected with pp60”“” 
Fig. 1. Morphology of neo control and pp60”c-transfected NIH3T3 
cells. Numbers in parenthesis indicate the kinase activity of pp60”. 
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Fig. 2. Antiproliferative effects of diRerent concentrations of TNF 
against neo and pp60”“-transfected NIH3T3 cells. 5 x 10’ cells/well in 
0.1 ml were incubated with varying concentrations of human TNF 
(upper panel) and murine TNF (lower panel) in 96-well plates at 37’C 
for 72 h. The relative cell viability was determined by staining with 
crystal violet as described in section 2. All determinations were in 
triplicate. 
differ significantly in morphology from that of neo con- 
trol. Both control and pp60”‘-transfected cells were sol- 
ubilized with detergent and tested for tyrosine kinase 
activity. pp60’-“-transfected cells contained four times 
as much kinase activity as in control cells (2.4 vs. 0.6 
units/lo6 cells). 
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Fig. 3. The effect of hTNF on the growth rate of neo (left panel) and ~~60”“’ (right panel)-transfected NIH3T3 cells. 5 x l@ cells/well in 1 ml were 
incubated in the presence or absence of TNF (20 ng/ml) in 24-well plates at 37°C. At indicated times cell number was determined by Trypan blue 
exclusion method as described in section 2. All determinations were in duplicate. 
3.2. NIH-3T3 cells trarqfected with pp60v- are resl;rtant 
to TNF 
First we examined the antiproliferative ffects of TNF 
by Crystal violet dye uptake on NIH3T3 cells transfected 
with either neo (control) or pp60” genes. The control 
cells were growth inhibited by TNF in a dose-dependent 
manner (Fig. 2) whereas v-src-transfected cells were rela- 
tively resistant. At 200 ng/ml TNF, the growth inhibition 
of control and v-src-transfected cells was 75% and 20%, 
respectively (upper panel). Since hTNF binds only to the 
p60 form of the TNF receptor on murine cells, whereas 
murine TNF on murine cells binds to both the p60 and 
~80 receptor, we also examined the effect of murine 
TNF. The results also indicated that v-src-transfected 
cells were more resistant to murine TNF than control 
cells (Fig. 2; lower panel). At 20 ng/ml of murine TNF, 
the growth inhibition was approximately 80% for control 
and 35% for v-src-transfected cells. 
Since src-transfected cells grow faster than control 
cells, we also examined the effect of TNF on the growth 
rate of cells as determined by the change in viable cell 
number over time. The results of this experiment, shown 
in Fig. 3, indicated that in the presence of TNF the 
growth of control cells was completely inhibited for up 
to 4 days, whereas rc-transfected cells continued to pro- 
liferate at a rate only slightly slower than control cells. 
These results further co&m the role of pp60” kinase 
in induction of resistance to TNF. 
3.3. Cellular resktance to TNF by ~~60”” is not due to 
down-modulation of TNF receptors 
Previously we have shown that transfection of cells 
with HER2 oncogene leads to a resistance of cells to 
TNF that correlates with down modulation of TNF re- 
ceptors [lo]. Therefore, we examined the effect of 
pp60”” transfection of cells on the TNF receptors. The 
results shown in Fig. 4 indicate that there was no statis- 
tically significant difference in the binding of TNF be- 
tween control and src-transfected cells. 
3.4. Cellular resistance to TNF induced by pp60”“” 
correlates with a decrease in intracellular glutathione 
levels 
We have reported [15] that cell density-dependent cel- 
lular resistance to TNF correlates with the decrease in 
intracellular glutathione levels; therefore, we examined 
glutathione levels in control and src-transfected cells. 
There was about 40% less glutathione in the src-trans- 
fected cells than in the neo control (Fig. 5). 
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Fig. 4. Specific binding of labeled hTNF to control and pp60”“-trans- 
fected NIH3T3 cells. 1 x lo6 cells (0.1 ml) in 96-well plates were incu- 
bated with different concentrations of labeled TNF either in the pres- 
ence (nonspecitic binding) or absence (total binding) of 100 nM unla- 
beled TNF for 1 h at 4°C. Thereafter cells were centrifuged and washed 
thrice, and cell-bound radioactivity counted. All determinations were 
made in triplicate. 
3.5. Cellular resistance to TNF induced by pp60vm” can 
be reversed by interferon-y 
We and others have shown that IFNs can potentiate 
the antiproliferative effects of TNF [ 16-211. Therefore, 
we examined the possibility that pp60’-““-induced cellu- 
lar resistance to TNF could be overcome by IFN-y. 
IFN-y had little effect on the anticellular effects of TNF 
on control cells, but under similar conditions, the 
pp60”“-transfected cells became sensitive when treated 
with TNF and IFN-y together (Fig. 6). Thus IFN-y 
could modulate the oncogene-induced resistance of cells 
to TNF. 
4. Discussion 
We report here that transfection of NIH-3T3 cells with 
pp60”+” leads to resistance to the antiproliferative ffects 
of TNF. The induction of resistance was not due to the 
modulation of TNF receptors; rather it correlated with 
a decrease in intracellular glutathione levels. Further- 
more, the cellular resistance to TNF could be overcome 
in part by IFN-y. 
Why some tumor cells are sensitive while others are 
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resistant o TNF is not understood. Previously, we have 
shown that tumor cells overexpressing HER2 are resis- 
tant to TNF [lo]. We now report that ~~60”~“” also in- 
duces TNF resistance, but not through modulation of 
TNF receptors as noted in case of HER.?. ~~60”” is 
expressed in several different types of tumor, including 
neuroblastomas, colon carcinoma, small cell lung carci- 
noma, bladder carcinoma, breast carcinoma and various 
other tumor cell lines [22-291. Furthermore, when my- 
eloid cell lines such as U937 and HL-60 are induced to 
differentiate by TNF and IFN-y, the expression of 
~~60’~” is enhanced [30]. Human tumor cell lines A-549 
(lung adenocarcinoma), HT29 (colon carcinoma) and 
SK-OV-3 (ovarian carcinoma) which overexpress c-m, 
are known to be resistant o TNF [3,4]. 
How ~~60”~“*” induces resistance to TNF is not clear. 
It has been shown, however, that TNF causes the growth 
inhibition and decrease of pp60”*“’ kinase activity of 
colon carcinoma cell lines in a dose-dependent manner 
[31]. No decrease in the kinase activity was observed in 
cell lines resistant o TNF. Recently we have shown that 
protein tyrosine phosphatases play an important role in 
TNF-mediated antiproliferative effects [32]. Since 
pp60”“” is a protein tyrosine kinase, it is possible that its 
effects on cellular resistance are mediated through inacti- 
vation of the protein tyrosine phosphatase pathway. The 
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Fig. 5. Intracelhtlar glutathione levels in control and pp60’“-trans- 
fected NIH3T3 cells. Bars represent the glutathione levels (mnol per mg 
of protein) in IWO and v-src-transfected NIH3T3 cells. 
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Fig. 6. The effect of hTNF and murine IFN-y on the of control (upper 
panel) and pp601”“’ (lower panel) transfected murine NIH3T3 cells. 
5 x 10’ cells/well in 1.0 ml were incubated with hlNF (20 ng/ml), 
mIFN-g (500 U/ml), and two together, in a 24-well plate at 37’C for 
72 h. The cell number was determined by the Trypan blue exclusion 
method. All determinations were made in duplicate. 
effect of tyrosine phosphatases on the activation of c-src 
kinase has been demonstrated [10,33]. We also found 
pp60”“- mediated cellular resistance leads to downmod- 
ulation of intracellular glutathione levels. This is consis- 
tent with our recent report showing an association be- 
tween cell-density-dependent resistance to TNF and a 
decrease in intracellular GSH levels [15]. Although it is 
not clear how ~~60”~‘~’ decreases GSH levels, ~~60”~“’ 
also appears to be related to cellular resistance to TNF. 
Since tumorigenesis is a result of altered expression of 
multiple oncogenes, it is possible that different onco- 
genes in different tumor cells contribute to the induction 
of resistance to TNF. Besides HER2 and pp60”“, the 
role of other oncogenes in induction of resistance to 
TNF, however, remains to be determined. 
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